Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Liver Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 33 articles: HTML format Text format

Single Articles

August 2019
1. LOW ESL, Patwala K, Apostolov R
   Dyspnoea, clubbing, cirrhosis, and bubbles in both sides of the heart suggests hepatopulmonary syndrome.
   Lancet. 2019;394:510.
   PubMed     Text format    
   
   
   
2. CHAPPELL LC, Bell JL, Smith A, Linsell L, et al
   Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
   Lancet. 2019 Aug 1. pii: S0140-6736(19)31270.
   PubMed     Text format     Abstract available
   
   
   
3. MARSCHALL HU
   Ursodeoxycholic acid for intrahepatic cholestasis in pregnancy.
   Lancet. 2019 Aug 1. pii: S0140-6736(19)31607.
   PubMed     Text format    
   
   
   July 2019
4. VIVANTI AJ, Voican C, De Luca D, Benachi A, et al
   Intrahepatic cholestasis: suggested future investigations.
   Lancet. 2019 Jul 1. pii: S0140-6736(19)31391.
   PubMed     Text format    
   
   
   
5. OVADIA C, Chappell LC, Williamson C
   Intrahepatic cholestasis: suggested future investigations - Authors' reply.
   Lancet. 2019 Jul 1. pii: S0140-6736(19)31389.
   PubMed     Text format    
   
   
   June 2019
6. HAWKINS P, Logan PM, Reeves EP, McElvaney NG, et al
   Pneumothorax and lung cysts: a family affair.
   Lancet. 2019;393:2635.
   PubMed     Text format    
   
   
   March 2019
7. LEVY S, Samuel D
   Prevention of decompensation in cirrhosis: a new youth for beta blockers.
   Lancet. 2019 Mar 22. pii: S0140-6736(19)30736.
   PubMed     Text format    
   
   
   
8. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
   beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
   Lancet. 2019 Mar 22. pii: S0140-6736(18)31875.
   PubMed     Text format     Abstract available
   
   
   
9. JANUSZEWICZ W, Corrie P, Liu H, Chan J, et al
   A sinister black finding in the stomach.
   Lancet. 2019;393:1149.
   PubMed     Text format    
   
   
   
10. CORNEC-LE GALL E, Alam A, Perrone RD
    Autosomal dominant polycystic kidney disease.
    Lancet. 2019;393:919-935.
    PubMed     Text format     Abstract available
    
    
    February 2019
11. OVADIA C, Seed PT, Sklavounos A, Geenes V, et al
    Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.
    Lancet. 2019 Feb 14. pii: S0140-6736(18)31877.
    PubMed     Text format     Abstract available
    
    
    
12. PALMER KR, Xiaohua L, Mol BW
    Management of intrahepatic cholestasis in pregnancy.
    Lancet. 2019 Feb 14. pii: S0140-6736(18)32323.
    PubMed     Text format    
    
    
    January 2019
13. BRAILLON A
    Laennec's cirrhosis.
    Lancet. 2019;393:131-132.
    PubMed     Text format    
    
    
    December 2018
14. WONG VWS, Adams LA
    Fibroblast growth factor 21 for non-alcoholic steatohepatitis.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)32165.
    PubMed     Text format    
    
    
    
15. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
    Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
    PubMed     Text format     Abstract available
    
    
    
16. SARGENT J, Horton R
    Transforming the landscape of liver disease in the UK.
    Lancet. 2018;392:2332-2333.
    PubMed     Text format    
    
    
    November 2018
17. CARACENI P, Roncadori A, Bernardi M
    Questions in the design of ANSWER - Authors' reply.
    Lancet. 2018;392:1623-1624.
    PubMed     Text format    
    
    
    
18. ROWE IA, Parker R
    Questions in the design of ANSWER.
    Lancet. 2018;392:1623.
    PubMed     Text format    
    
    
    August 2018
19. MANNS MP, Burra P, Sargent J, Horton R, et al
    The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities.
    Lancet. 2018;392:621-622.
    PubMed     Text format    
    
    
    July 2018
20. BARNETT R
    Liver cirrhosis.
    Lancet. 2018;392:275.
    PubMed     Text format    
    
    
    May 2018
21. GARCIA-TSAO G
    Long-term albumin in cirrhosis: is it the ANSWER?
    Lancet. 2018 May 31. pii: S0140-6736(18)30948.
    PubMed     Text format    
    
    
    
22. CARACENI P, Riggio O, Angeli P, Alessandria C, et al
    Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
    Lancet. 2018 May 31. pii: S0140-6736(18)30840.
    PubMed     Text format     Abstract available
    
    
    March 2018
23. CHARLTON M
    FGF-19 agonism for NASH: a short study of a long disease.
    Lancet. 2018;391:1124-1126.
    PubMed     Text format    
    
    
    
24. REIG M, Bruix J
    Lenvatinib: can a non-inferiority trial change clinical practice?
    Lancet. 2018;391:1123-1124.
    PubMed     Text format    
    
    
    
25. HARRISON SA, Rinella ME, Abdelmalek MF, Trotter JF, et al
    NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2018 Mar 5. pii: S0140-6736(18)30474.
    PubMed     Text format     Abstract available
    
    
    February 2018
26. KUDO M, Finn RS, Qin S, Han KH, et al
    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Lancet. 2018 Feb 9. pii: S0140-6736(18)30207.
    PubMed     Text format     Abstract available
    
    
    January 2018
27. PATTEN DA, Shetty S
    Chronic liver disease: scavenger hunt for novel therapies.
    Lancet. 2018;391:104-105.
    PubMed     Text format    
    
    
    
28. FORNER A, Reig M, Bruix J
    Hepatocellular carcinoma.
    Lancet. 2018 Jan 4. pii: S0140-6736(18)30010.
    PubMed     Text format     Abstract available
    
    
    August 2017
29. SCHACHTER J, Ribas A, Long GV, Arance A, et al
    Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31601.
    PubMed     Text format     Abstract available
    
    
    April 2017
30. WORNS MA, Galle PR
    Immune oncology in hepatocellular carcinoma-hype and hope.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31044.
    PubMed     Text format    
    
    
    
31. EL-KHOUEIRY AB, Sangro B, Yau T, Crocenzi TS, et al
    Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31046.
    PubMed     Text format     Abstract available
    
    
    February 2017
32. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
    PubMed     Text format     Abstract available
    
    
    November 2016
33. KIRBY T
    Profile: The Kirby Institute celebrates 30 years.
    Lancet. 2016;388:2466.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: